Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791929 | 0.88 | CHRM2 (0.52) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL5870742 | 0.88 | CHRM2 (0.52) | CHRM1CHRM2CHRM3HSD11B1CCR3 | |
| SCHEMBL13791337 | 0.87 | CHRM2 (0.55) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL5870725 | 0.82 | CHRM2 (0.49) | CHRM1CHRM2CHRM3HSD11B1CCR3 | |
| SCHEMBL18418205 | 0.80 | KCNK3 (0.48) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL4773466 | 0.80 | TP53 (0.54) | CCR3GPR119 | |
| SCHEMBL17296109 | 0.79 | NAMPT (0.48) | CCR3 | |
| SCHEMBL6758133 | 0.79 | CHRM2 (0.54) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL6761176 | 0.79 | CHRM2 (0.54) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL20989367 | 0.79 | CHRM2 (0.54) | CHRM1CHRM2CHRM3HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | CHRM1 1611/4885CHRM2 2308/4885CHRM3 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.